There's A Lot To Like About Shandong Weigao Group Medical Polymer's (HKG:1066) Upcoming CN¥0.0919 Dividend
There's A Lot To Like About Shandong Weigao Group Medical Polymer's (HKG:1066) Upcoming CN¥0.0919 Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) is about to go ex-dividend in just three days. Typically, the ex-dividend date is one business day before the record date which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Thus, you can purchase Shandong Weigao Group Medical Polymer's shares before the 18th of October in order to receive the dividend, which the company will pay on the 22nd of November.
有些投资者依赖分红来增加财富,如果你是其中一位分红分析师,你可能会感兴趣知道,山东威高股份医疗聚合物有限公司(HKG:1066)将在三天后进行除息。通常,除息日是股权登记日之前的一个工作日,股权登记日是公司确定股东有资格获得分红的日期。除权日很重要,因为股票上的任何交易在股权登记日之前必须已经结算,才有资格获得分红。因此,你可以在10月18日之前购买山东威高股份医疗聚合物的股票,以便在11月22日收到公司支付的股息。
The company's next dividend payment will be CN¥0.0919 per share, and in the last 12 months, the company paid a total of CN¥0.17 per share. Based on the last year's worth of payments, Shandong Weigao Group Medical Polymer has a trailing yield of 3.3% on the current stock price of HK$5.51. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.
公司的下一个分红支付金额将是CN¥0.0919每股,过去12个月,公司每股总计支付了CN¥0.17。根据去年的支付情况,山东威高股份医疗聚合物在当前股价HK$5.51上拥有3.3%的滚动收益率。分红对于长期持有者的投资回报是一个主要贡献因素,但前提是分红持续支付。这就是为什么我们应该始终检查分红支付是否可持续,以及公司是否在成长。
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Fortunately Shandong Weigao Group Medical Polymer's payout ratio is modest, at just 44% of profit. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. It distributed 36% of its free cash flow as dividends, a comfortable payout level for most companies.
通常,分红是由公司盈利支付的。如果公司支付的分红超过其盈利,那么分红可能就不可持续了。幸运的是,山东威高股份医疗聚合物的派息比率很适中,仅为利润的44%。然而,现金流通常比利润更重要,用于评估分红的可持续性,因此我们应始终检查公司是否产生足够的现金来支付其分红。它将36%的自由现金流作为分红进行分配,对于大多数公司来说是一个舒适的分红水平。
It's positive to see that Shandong Weigao Group Medical Polymer's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.
看到山东威高股份医疗聚合物的分红既由利润又由现金流覆盖是积极的,因为这通常表示分红是可持续的,较低的派息比率通常意味着在分红被删减之前有更大的安全性保障。
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
点击此处查看公司的支付比率以及未来分红的分析师预期。
Have Earnings And Dividends Been Growing?
收益和股息一直在增长吗?
Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. With that in mind, we're encouraged by the steady growth at Shandong Weigao Group Medical Polymer, with earnings per share up 4.9% on average over the last five years. Earnings per share growth in recent times has not been a standout. Yet there are several ways to grow the dividend, and one of them is simply that the company may choose to pay out more of its earnings as dividends.
具有持续增长每股收益的公司通常是最佳的分红股票,因为他们通常更容易增加每股分红。如果企业进入衰退阶段并且分红被削减,公司的价值可能会急剧下降。考虑到这一点,我们对山东威高股份医疗聚合物持续稳定增长感到鼓舞,过去五年平均每股收益增长4.9%。近年来,每股收益增长并不突出。然而,有几种增加分红的方法,其中之一是公司可能选择将更多收益作为分红支付。
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Shandong Weigao Group Medical Polymer has delivered an average of 11% per year annual increase in its dividend, based on the past 10 years of dividend payments. We're glad to see dividends rising alongside earnings over a number of years, which may be a sign the company intends to share the growth with shareholders.
衡量公司分红前景的另一个关键方式是通过其历史分红增长率。基于过去10年的分红支付,山东威高股份医疗聚合物的平均年度分红增长率为11%。我们很高兴看到分红随着收益一起在多年内上升,这可能是公司打算与股东分享增长的迹象。
Final Takeaway
最后的结论
From a dividend perspective, should investors buy or avoid Shandong Weigao Group Medical Polymer? Earnings per share have been growing moderately, and Shandong Weigao Group Medical Polymer is paying out less than half its earnings and cash flow as dividends, which is an attractive combination as it suggests the company is investing in growth. It might be nice to see earnings growing faster, but Shandong Weigao Group Medical Polymer is being conservative with its dividend payouts and could still perform reasonably over the long run. Overall we think this is an attractive combination and worthy of further research.
从分红的角度来看,投资者应该买入还是避免购买山东威高医疗聚合物集团?每股收益增长适中,山东威高医疗聚合物集团支付的股息不到其盈利和现金流的一半,这是一个有吸引力的组合,表明公司正在投资于增长。希望看到盈利增长更快,但山东威高医疗聚合物集团在分红方面保守,长期来看仍然有不错的表现。总体来说,我们认为这是一个有吸引力的组合,值得进一步研究。
With that in mind, a critical part of thorough stock research is being aware of any risks that stock currently faces. In terms of investment risks, we've identified 1 warning sign with Shandong Weigao Group Medical Polymer and understanding them should be part of your investment process.
考虑到这一点,彻底研究股票的重要部分是意识到该股目前面临的任何风险。在投资风险方面,我们已经发现了山东威高医疗聚合物集团的1个警示信号,了解这些风险应该成为您投资过程的一部分。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
一般来说,我们不建议仅仅购买第一个股息股票。下面是一个经过策划的有趣的、股息表现良好的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。